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i-1.ccelerated Growth Rates of Recurrent 
Hepatocellular Carcinoma After 
Liver Transplantation 
rtsuo Yokoyama, MD, Brian Carr, MD, PhD, Hideki Saitsu. MD, 
Shunzaburo Iwatsuki, MD, and Thomas E. Starzl, MD, PhD 
The growth rates of recurrent hepatocellular carcinoma (HCCl after orthotopic 
liver transplantation (OLTX) were estimated by calculating the tumor doubling 
time (TDT) in 20 patients. The mean TDT, calculated by multiple measurement of 
tumor size, was 44.3 ± 11.3 days (mean ± standard error) in 12 patients with 
pulmonary metastasis (range, 10 to 161 days) and 37.6 ± 8.9 days (range, 7 to 65 
days) in 5 patients with liver allograft recurrence. The TDT as estimated by serum· 
alpha-fetoprotein (AFP) levels in 6 patients was 37.3 ± 10.0 days (range, 12 to 84 
days). The mean TDT obtained from 5 control subjects with HCC who were treated 
with liver resection (without immunosuppression) was 273.8 ± 79.1 days (range, 82 
to 560 days). The disease-free period and survival time after OLTX both correlated 
well with the TDT (r = 0.546 and r = 0.701, respectively). The patients with 
fibrolamellar HCC had a greater TDT and a longer survival time than those with 
nonfibrolamellar HCC. Despite a wide range of TDT in patients who received 
transplants, their recurrent HCC tumors grew significantly faster than those of 
patients with the same disease who did not receive transplants. The factors 
involved in this accelerated growth rate may include the use of immunosuppressive 
drugs and the consequent suppression of host immunity against the growth of 
micro metastasis. Cancer 68:2095-2100 • 
PATIENT SUR YIV AL after orthotopic liver transplan-
tation (OL TX) for primary hepatic m~ant ~s­
ease is hampered by tumor recurrence. Also, survival time 
is significantly lower than that for nonmalignant liver dis-
eases. l -6 It has been speculated that immunosuppressive 
therapy accelerates tumor growth,I.7-8 but this has not 
been documented in clinical transplantation. 
In this study, we examined the growth rates of recurrent 
hepatocellular carcinomas (HCC) after OL TX during im-
munosuppressive therapy by calculating tumor doubling 
time (TDT). The growth rates during immunosuppression 
were compared with those after hepatic resection without 
immunosuppression and to those reported in the litera-
ture. 
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Patients and Methods 
Between January 1980 and July 1989, 100 patients with 
HCC underwent OLTX at the University Health Sciences 
Center of Colorado (1980) and the University Health 
Center of Pittsburgh (since 1981). 
All patients received cyclosporine and steroid combi-
nation therapy as basic immunosuppression. Some pa-
tients received adjuvant chemotherapy that primarily 
consisted of doxorubicin (Adriamycin, Adria Laborato-
ries, Columbus, OH) in varying doses and schedules, 
without a uniform protocol. Once recurrent disease was 
diagnosed, most patients received some form of chemo-
therapy. 
Tumor recurrence was documented in 43 of 100 pa-
tients(43%) during the median follow-up time of 34 
months (range, 12 to 124 months). The size of the recur-
rent tumor could be measured in 27 lesions (15 in the 
liver allograft and 12 in the lung) of 20 patients. In 17 of 
the 27 lesions (L2 in the lung and 5 in the liver), the size 
of the tumor could be measured on mUltiple occasions. 
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The size of the recurrent tumor in the liver allograft 
was measured by computed tomography (consecutive 
sections were ~ 1.0-cm thick) in 13 patients (at autopsy 
in 1 patient and at surgery in 1 patient). The size of the 
metastatic lesions in the lung was measured by a chest 
radiograph. , .' ~ 
Five patients who un.derwent liv~r resection only for 
HCC and whose tumors.were resected were used as control 
subjects for comparison of TDT with the patients who 
underwent transplantation and immunosuppression. 
All of the recurrent tumors were 5 cm or less in greatest 
diameter at the time of diagnosis of the recurrence. 
The TDT was calculated by the following formula de-
veloped by Schwartz:9 
. ') t log (2) 
TDT (tumor doubling tIme = 3 log (Du'Dl) 
where D (DI or D2) is a mean value of the largest diameter 
and a diameter perpendicular to it, in millimeters. DI is 
the tumor diameter at the first measurement, D2 is the 
tumor diameter at the second measurement, and t is the 
time interval (days) between the measurements (two-point 
measurement). When the TOT were obtained on multiple 
occasions, the average value of the growth rates was used. 
In ten patients for whom only a single time point mea-
surement was available, the TOT was calculated based 
on the assumption that the size of the microdeposits of 
the original HCC was 1 mm in diameter (DI = 1; one-
point measurement). Based on this assumption, TOT was 
calculated when DI was given an arbitrary value of 1 in 
the above formula. 
Serum alpha-fetoprotein (AFP) levels have been used 
for estimations of TOT in other studies. IO Therefore, in 
this study we correlated changes in AFP levels with ob-
jective tumor measurement in some of the patients to 
compare the values obtained by these two methods. 
Linear regression analysis was used to evaluate the re-
lationship between TOT and survival time or the disease-
free period. The chi-square analysis and Student's t test 
were used to compare the differences between the groups. 
The difference was considered significant when the P value 
was less than 0.05. 
Results 
The TOT and other clinical information for 20 patients 
who underwent OLTX is summarized in Table 1. The 
TDT was obtained by two-point measurement in 5 of 15 
TABLE 1. Tumor Doubling Time in 20 Patients With Liver Transplantation 
Tumor douhling tumor (days) 
Case no. 
(OLT no.) 
231 
324 
338 
344 
454 
462 
767 
1012 
1116· 
1132 
1280* 
1466 
1605 
1659 
1683 
1684 
1802 
1838 
1903 
2076 
Mean 
SE (day) 
No, 
CIR 
+ 
+ 
+ 
+ 
+ 
-+ 
+ 
+ 
+ 
+ 
+ 
+ 
HB 
+ 
+ 
+ 
+ c 
FL-HCC 
+ 
+ 
Two-point 
measurement 
51 
7 
Liver 
CIR: cirrhosis; HB: hepatitis-B surface antigen-positive; FL-HCC: Ii-
brolamellar hepatocellular carcinoma; AFP: alpha-fetoprotein; PST: pa-
tient survival time; DFP: disease-free period; SE: standard error. 
One-point 
measurement 
II 
32 
45 
9 
8 
5 
24 
4 
10 
28 
14 
II 
28 
29 
12 
18.0 
3.0 
15 
Lung 
73 
46 
161 
18 
S8 
37 
10 
15 
14 
54 
27 
19 
44.3 
11.3 
12 
AFP 
levelt 
12 
84 
52 
27 
17 
32 
37.3 
10.0 
6 
PST (mo) 
83.0 
16.1 
31.7 
23.4 
5.6 
11.7 
28.8 
16.9 
S.3 
12.9 
31.9 
4.6 
7.5 
17.6 
21.3 
13.0 
S.3 
17.8 
16.0 
' 5.7 
18.2 
3.7 
21 
* No chemotherapy given during the observation period. 
DFP (mo) 
12.9 
5.0 
20.7 
17.4 
2.6 
3.9 
10.8 
9.0 
3.5 
4.2 
8.2 
2.9 
5.2 
0.0 
11.7 
7.3 
5.6 
12.0 
9.5 
5.2 
7.6 
1.1 
21 
t The values estimated by the time required for the doubling of the 
AFP level. 
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TABLE 2. Tumor Doubling Time for Four Patients 
With Liver Resection 
Tumor doubling time 
. (days) (two-point 
Use no .. CIR HB FL-HCC measurement) PST DFP 
+ 560 86.2 43.9 
2 l- T - 351 39.2 3.8 
3 -: 96 30.8 22.0 
4- 82 
Mean (day) 272.5 52.1 23.2 
SE 98.8 14.1 9.S 
No. 4 3 3 
CIR: cirrhosis; HB: hepatitis-B surface antigen-positive; FL-HCC: fi-
bre-lamellar hepatocellular carcinoma; PST: patient survival; DFP: dis-
ease-free period; SE: standard error. 
• Tumor size measured before liver resection. 
patients who had tumor recurrence in the liver allograft. 
The mean TOT was 33.0 ± 7.1 days. One patient with 
fibrolamellar HCC had the longest TOT of 51 days. The 
mean TOT for nonlibrolamellar HCC was 29.5 ± 7.4 
dJ. ys (four patients) (Table 1). These values were compared 
with those of 5 control subjects with recurrent HCC after 
liver resection (with no immunosuppression), in whom 
the mean TOT was 273.8 ± 79.1 days (Table 2). One 
patient with librolamellar HCC had the longest TOT of 
560 days after liver resection. The mean TOT for nonfi-
brolamellar HCC in this group was 202.3 ± 58.1 days 
(four patients), which was significantly longer than that 
for recurrent tumor after OL TX (P < 0.001). 
The mean TOT for the pulmonary metastases in 12 
patients was 44.3 ± 12.1 days. Two patients with libra-
200 
100 
- ~ E 50 g a: 
FiG. 1. The diameter of the met- W 
astatic tumors is plotted on the log- tu 20 
arithmic scale in relation to the time ::E « 
after OLTX for HCC in 12 patients 0 
with pulmonary metastasis (includ- a: 10 ing 2 patients with fibrolamellar a 
HCC). ::E 
~ 5 
2 
1 
0 
lamellar HCC had the longest TOT (161 and 73 days), 
and the mean TDT for nonfibrolamellar HCC was 29.8 
± 5.3 days (ten p.atients) (Table 1). No difference was 
noted between the TDT of liver allograft and pulmonary 
recurrences in. patients with nonfibrolamellar HCC. 
The mean TOT obtained from serum AFP levels in 6 
patients with nonfibrolamellar HCC was 37.3 ± 10.0 days 
(Table 1). This value was not significantly different from 
the TOT calculatoo by the tumor sizes of the liver allograft 
recurrences or pulmonary metastases. 
The TOT obtained by one-point measurement in 15 
patients with allograft recurrence was 18.0 ± 3.1 days 
(Table 1), which was shorter than that obtained by two-
point measurement. However, when a comparison was 
made with four patients with nonfibrolamellar HCC who 
were available for two-point measurement, the mean TOT 
by one-point measurement was 22.5 ± 4.0 days, which 
was not significantly different from that obtained by two-
point measurement. 
The change in tumor diameter during the time after 
OL TX in 12 patients with pulmonary metastasis is shown 
in Figure 1. One patient had temporary regression of the 
tumor and another patient had tumor growth retardation 
after initiation of aggressive chemotherapy. In three other 
patients, however, the tumor growth rate was relatively 
constant at each time point measured despite chemo-
therapy. One of the patients with the shortest TOT (10 
days) did not receive any anti-cancer treatment. 
Tumor growth curves were similar for 15 patients with 
allograft recurrence (Fig. 2). For those whose tumor size 
was measured twice, tumor growth rates between two sets 
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FIG. 2. The diameter of the re-
current HCC in liver allografts is 
ploned in relation to the time after 
OLTX in 15 patients, including 1 
patient with fibrolame11ar HCC. In 
five patients, tumor size was mea-
sured twice and the resulting tumor 
growth curves are shown. Tumor 
growth curves were generated by 
both two-point and one-point mea-
surements. -~ 
of different time points were similar. The shortest TOT 
(4 days) was seen in a patient with positive hepatitis-B 
surface antigen and cirrhosis (Fig. 2 and Table 1). 
Tumor growth curves were also obtained for five pa-
tients who underwent liver resection (Fig. 3). Their clinical 
information and TOT are shown in Table 2. 
The survival time of the 20 patients ranged from 4.6 
to 83.0 months (mean, 18.2 ± 3.7 months). Their disease-
free period ranged from 0 to 20.7 months (mean, 7.6 ± 1.1 
months). Of two patients with fibrolamellar HCC, one 
had the longest survival time and the other had the longest 
disease-free period (Table 1). The survival time and dis-
ease-free period were plotted against TOT (Fig. 4). The 
shorter the TOT, the shorter the survival time and disease-
free period (P < 0.0001 and P < 0.0001, respectively). 
Tumor recurrence was noted within 12 months after 
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FIG. 3. The diametcr of the tumor 
(three patients with nonfibrolamellar 
HCC and one patient with librola-
me11ar HCC without immuno-
suppression therapy) and tumor 
growth curves in relation to time are 
shown. . 
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FIG. 4. (Top) Survival times of 20 patients with HCC are plotted in 
relation to TOT with significant correlation. (Bottom) A significant cor-
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OLTX in all but one of the patients with nonftbrolameilar 
HCC with TOT of less than 50 days (majority). All but 
one of these patients died within 24 months (Ftg. 4). 
Discussion 
Tumor growth rate can be a useful predictor of surviVal 
because it is an indicator of the biologic nature of the 
tumor. Clinically, the tumor grOwth rate has been found 
to be inversely proportional to both the length of the dis-
ease-free period and the survival rate.1I- 11 . , :;", •. 
The literature on TOT in HCC has been minimal. Us-
ing ultrasonography, Sheu et al. obtained TOT of 29 to 
398 days (mean, 136 days) for 28 patients with small HCC 
(~ 5 em in diameter), most of whom had cirrhotic liVers.13 
The TOT for the two noncirrhotic livers were 44 and 76 
days. In a similar study reported by Ebara et aI., I" the 
TOT for 21 patients with small HCC (~ 3 em in diameter) 
in cirrhotic livers was 30 to 540 days (mean, 195 days). 
Okazaki et al. found that the average TOT for IS patients 
with HCC (in 10 cirrhotic and 5 noncirrhotic livers) was 
102 days (range, 41 to 305 days). 15 The average TOT for 
the five noncirrhotic livers in this study was 132 days 
(range, 39 to 226 days). These findings provide further 
support for the belief that many ncc are slow-gro\ving 
tumors.-
Johnson and Williams studied 40 patients with HCC 
who underwent various treatments (including liver trans-
plantation) and showed that the TOT calculated by serum 
AFP level could be used for estimation of tumor pro-
gression. 10 They reported that the TOT ranged from 6.5 
to 112 days (mean, 41 days) for all of the patients. In two 
of six patients who underwent OLTX, recurrence was 
suspected when the AFP level rose. In this study, TOT' 
for the patients who underwent immunosuppression were 
not compared with those for the patients who did not 
undergo immunosuppression. However, the slope of the 
accompanying figures plotting time against AFP level il-
lustrated that TOT was markedly shortened compared 
with the other group of patients. AFP level would be ex-
pected to correlate' with viable tumor mass rather than 
tumor size.14 In fact, serum AFP level usually does not 
reflect the size of the tumor in humans,15-16 in contrast 
to animal. studieS. 17 In the current study, however, TOT 
for AFP level were comparable with those obtained for 
tumor volume. 
In the current study, the TOT for HCC after liver 
transplantation (under immunosuppression) was less than 
SO days in most of the cases when one-point or two-point 
measurement was used. Notable exceptions were patients 
with fibrolamellar HCC. We found that the growth rate 
of the recurrent tumors in patients receiving immuno-
suppression is significantly greater than that of those who 
are not receiving immunosuppression. This indicates that 
immunosuppression may play a major role in the pro-
gression of tumor recurrence in the complex post-OLTX 
settinp. 
Because it is unlikely that tumors develop de novo in 
the liver allograft within 1 or 2 years after liver transplan-
tation, recurrent HCC is likely the result of either metas-
tasis from undiagnosed distant metastases that bad been 
present before OLTX, or spillage of cancer cells at the 
time of surgical manipulation." Therefore, recurrent HCC 
in the liver allograft must be secondary to the arrest of a 
cluster of cancer cells in the blood vessels that have escaped 
from the original tumors. The estimated tumor diameter 
of 1 mm may be an over-calculation because the diameter 
of the microvessels is much smaller. Moreover, if the size 
of the initial metastatic implant was less than 1 mm in 
diameter, the TOT of the recurrent HCC in the liver al-
lograft would become even shorter. 
Immunosuppression has been thought to accelerate re-
sidual tumor growth in humans after liver transplanta-
2100 CANCER November 15 1991 Vol. 68 
tion.10 Animal studies have shown that in many tumor 
systems that can be transplanted, depression of host im-
munity increases the incidence of tumor metastasis. 18-20 
Natural host defense mechanisms against tumor cells me-
diated by natural killer cells are belie~ed to become im-
paired by immunosuppressive drugs that depress cell-me-
- diated immunity.21 
Cytokines, bacterial endotoxin, or coagulation factors-
(humoral factors that are released during the perioperative 
period of liver transplantation) may also play a role in 
tumor progression.22- 23 They alter endothelial surface 
properties, enhancing metastasis formation,24 or directly 
damage the liver parenchyma, which may increase the 
metastatic potential of the liver.25- 26 
Despite the complexity of the mechanisms in. tumor 
metastasis after liver transplantation, the current study 
demonstrates that the growth rate of recurrent HCC is 
markedly increased in the patient who receives a liver 
transplant along with immunosuppression. Further un-
derstanding of metastatic tumor biology and sophisticated 
use of immunosuppressive agents may contribute to 
prolonging patient survival after liver transplantation 
for HCC. 
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